Navigation Links
BioDelivery Sciences Announces the Hiring of Adrian Hepner, M.D. as Vice President of Clinical Research & Regulatory Affairs
Date:7/23/2013

earch in Latin America for TEVA Pharmaceuticals.

Dr. Hepner will initially concentrate on the clinical development program for Clonidine Topical Gel for the treatment of Painful Diabetic Neuropathy, which is expected to begin later this year. His prior experience and clinical research in this disorder will be instrumental in leading the Clonidine Topical Gel development program.

About BioDelivery Sciences International

BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction. 

BDSI's pain franchise currently consists of three products, two of which utilize the patented BioErodible MucoAdhesive (BEMA) drug delivery technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it is marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.). 

BDSI's second pain product using the BEMA technology, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is licensed on a worldwide basis to Endo Health Solutions.  BDSI's third pain product in development is Clonidine Topical Gel for the treatment of painful diabetic neuropathy and was recently licensed from Arcion Therapeut
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioDelivery Sciences to Present at the William Blair 33rd Annual Growth Stock Conference
2. BioDelivery Sciences to Present at the Jefferies 2013 Global Healthcare Conference
3. BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
4. BioDelivery Sciences Appoints Thomas W. DAlonzo to Board of Directors
5. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2012 Annual Report
6. BioDelivery Sciences to Present at the 25th Annual ROTH Conference
7. BioDelivery Sciences to Host Buprenorphine Investor and Analyst Event
8. BioDelivery Sciences to Present at the 15th Annual BIO CEO and Investor Conference
9. BioDelivery Sciences Announces Completion of BNX Safety Study
10. BioDelivery Sciences Announces $40 Million Registered Financing
11. BioDelivery Sciences to Present at the 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... revenues for the fourth quarter of 2013 will be ... approximately $208 million. "Our full-year revenue growth ...
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... NEWTON, Mass., May 22, 2012  Halo Therapeutics, LLC, ... rare fibrotic diseases, announced today that it has ... foundations serving the muscular dystrophy patient community. Halo ... 2 study of HT-100, its lead drug candidate ...
... Company, a Medicare Part D provider with offices in ... in the arbitration between the company and ProCare, its ... following a suit against ProCare based on Fox,s allegations ... 2012, the U.S. District Court for the Northern District ...
Cached Medicine Technology:Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100 2Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100 3Judge Upholds $3.3 Million Judgment In Favor of Fox Insurance Company Against Former Pharmacy Benefit Manager 2
(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... a study published today in PLOS Pathogens , ... malaria is common can mount an immune response to ... avoid repeated bouts of high fever and illness and ... bloodstream. The findings may help researchers develop future interventions ... malaria parasite. , Each year, approximately 200 million cases ...
(Date:4/17/2014)... In a review published in the April issue of ... The Feinstein Institute for Medical Research, says it,s time ... approach to treating sepsis, which kills millions ... Sepsis occurs when molecules released into the bloodstream to ... body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... prevalent in Mali with 90% women getting circumcised in ... , ,The circumcision are performed by witch doctors ... million women worldwide have been subjected to genital mutilation ... awareness of the dangers of such practices making the ...
... Illinois at Urbana-Champaign have developed a simple, disposable sensor ... the performance of much more sophisticated laboratory instruments. ... for assessing uranium contamination in the environment, and the ... professor at Illinois and senior author of a paper ...
... of Veterinary Medicine have derived uniparental embryonic stem cells ... sperm - and, for the first time, successfully used ... in adult mice. Their findings demonstrate that ... organ and could provide a less controversial alternative to ...
... 340 grams of omega-3-rich seafood per week during pregnancy ... in the children, says a new study. ... of seafood consumption during pregnancy, which state women should ... avoid exposing the foetus to trace amounts of pollutants ...
... have come out with a device which is likely// ... bladder control issues. ,They have named ... urinary circuit in spinal cord which is responsible for ... to sustain continence. This device is extremely useful in ...
... lasercomb which promises hair growth in the scalp has been ... Lasercomb is manufactured by Lexington International LLC, a Florida based ... laser technology in a comb which when passed through the ... both men and women. The company’s website reveals that they ...
Cached Medicine News:Health News:DNA-based Detection of Heavy Metals 2Health News:'single–parent' stem cells to replace adult mice organ 2Health News:'single–parent' stem cells to replace adult mice organ 3Health News:Fish Intake Linked to Higher IQ in Offspring 2Health News:Bladder Pacemaker For Incontinence 2Health News:Bladder Pacemaker For Incontinence 3
... Product features of the Mastercycler ep ... Gradient blocks with SteadySlope technology ... a stand-alone device, a Mini-Satellite system, or ... ESP technology (Electronic Sample Protection) Optional motorized ...
... features of the Mastercycler ep Extremely ... blocks with SteadySlope technology Intuitive graphic ... device, a Mini-Satellite system, or a PC-controlled ... (Electronic Sample Protection) Optional motorized lid for ...
... The DNA Engine instrument is ... Unprecedented thermal uniformity and ... and block-to-block. This rugged ... cycler, it's a platform for new ...
... Start up kit. Includes configured Laptop PC ... 1 MultiBlock satellite thermal Cycler (non-robotic). ... User friendly software. Store/track run data. ... lid. Outstanding uniformity. Advanced control ...
Medicine Products: